id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-3101-0022,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Guidance for Industry; Availability,Notice,Notice of Availability,2025-06-16T04:00:00Z,2025,6,2025-06-16T04:00:00Z,,2025-06-16T17:46:03Z,2025-10922,0,0,09000064b8e12d9a
FDA-2017-D-3101-0023,FDA,FDA-2017-D-3101,ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Guidance for Industry - Final Guidance,Other,Guidance,2025-06-16T04:00:00Z,2025,6,2025-06-16T04:00:00Z,,2025-06-16T18:00:16Z,,1,0,09000064b8e12f76